Cargando…
Immunogenicity and Safety of a Newly Developed Live Attenuated Varicella Vaccine in Healthy Children: A Multi-National, Randomized, Double-Blinded, Active-Controlled, Phase 3 Study
Korean manufacturers have developed a new varicella vaccine, NBP608. This phase 3, randomized, double-blind, multicenter study aimed to compare the immunogenicity and safety of NBP608 in healthy children to those of Varivax(TM) (control). Children aged 12 months to 12 years were randomized in a rati...
Autores principales: | Choi, Ui Yoon, Kim, Ki Hwan, Cho, Hye-Kyung, Kim, Dong Ho, Ma, Sang Hyuk, Choi, Young Youn, Kim, Chun Soo, Capeding, Maria Rosario, Kobashi, Ilya Angelica Rochin, Kim, Hun, Ryu, Ji Hwa, Lee, Su Jeen, Park, Ho Keun, Kim, Jong-Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537027/ https://www.ncbi.nlm.nih.gov/pubmed/37766093 http://dx.doi.org/10.3390/vaccines11091416 |
Ejemplares similares
-
Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial
por: Choi, Ui Yoon, et al.
Publicado: (2021) -
Induction of immunogenic cell death of tumors by newly synthesized heterocyclic quinone derivative
por: Son, Keum-joo, et al.
Publicado: (2017) -
Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
por: Song, Joon Young, et al.
Publicado: (2023) -
Evaluation of Immunogenicity and Safety of the New Tetanus-Reduced Diphtheria (Td) Vaccines (GC1107) in Healthy Korean Adolescents: A Phase II, Double-Blind, Randomized, Multicenter Clinical Trial
por: Rhim, Jung-Woo, et al.
Publicado: (2013) -
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial
por: Song, Joon Young, et al.
Publicado: (2022)